StreetInsider.com News Articles

iOnctura appoints Paul Sekhri as Chair of its Board of Directors

Thu, 15 Oct 2026 03:30:00 -0400

Paul Sekhri is a life science executive with more than 35 years of experience building and leading companies from early development through commercialization
Appointment comes as iOnctura prepares for late-stage development of roginolisib, with its two randomized studies fully enrolled
Strengthens iOnctura’s Board with extensive experience in company building, strategic transactions and financing

GENEVA, AMSTERDAM and CAMBRIDGE, Mass., Oct. 15, 2026 (GLOBE NEWSWIRE) -- iOnctura, a clinical-stage precision oncology company combating neglected and hard-to-treat cancers, today announces the appointment of Paul Sekhri as Chair of its Board of Directors with

iOnctura appoints Paul Sekhri as Chair of its Board of Directors

Thu, 15 Oct 2026 03:30:00 -0400

Paul Sekhri is a life science executive with more than 35 years of experience building and leading companies from early development through commercialization
Appointment comes as iOnctura prepares for late-stage development of roginolisib, with its two randomized studies fully enrolled
Strengthens iOnctura’s Board with extensive experience in company building, strategic transactions and financing

iOnctura appoints Paul Sekhri as Chair of its Board of Directors

Thu, 15 Oct 2026 03:30:00 -0400

Paul Sekhri is a life science executive with more than 35 years of experience building and leading companies from early development through commercialization
Appointment comes as iOnctura prepares for late-stage development of roginolisib, with its two randomized studies fully enrolled
Strengthens iOnctura’s Board with extensive experience in company building, strategic transactions and financing

iOnctura appoints Paul Sekhri as Chair of its Board of Directors

Thu, 15 Oct 2026 03:30:00 -0400

Paul Sekhri is a life science executive with more than 35 years of experience building and leading companies from early development through commercialization
Appointment comes as iOnctura prepares for late-stage development of roginolisib, with its two randomized studies fully enrolled
Strengthens iOnctura’s Board with extensive experience in company building, strategic transactions and financing

iOnctura appoints Paul Sekhri as Chair of its Board of Directors

Thu, 15 Oct 2026 03:30:00 -0400

Paul Sekhri is a life science executive with more than 35 years of experience building and leading companies from early development through commercialization
Appointment comes as iOnctura prepares for late-stage development of roginolisib, with its two randomized studies fully enrolled
Strengthens iOnctura’s Board with extensive experience in company building, strategic transactions and financing

iOnctura appoints Paul Sekhri as Chair of its Board of Directors

Thu, 15 Oct 2026 03:30:00 -0400

Paul Sekhri is a life science executive with more than 35 years of experience building and leading companies from early development through commercialization
Appointment comes as iOnctura prepares for late-stage development of roginolisib, with its two randomized studies fully enrolled
Strengthens iOnctura’s Board with extensive experience in company building, strategic transactions and financing

vTv Therapeutics Announces Oral Presentation at Breakthrough T1D Clinical and Research Congress 2026

Sat, 10 Oct 2026 08:00:00 -0400

New research spotlights hypoglycemia-related burdens in adults with type 1 diabetes using automated insulin delivery systems

HIGH POINT, N.C., Oct. 10, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company advancing cadisegliatin, a novel oral investigational therapy for type 1 diabetes (T1D), today announced that Chief Medical Officer Thomas Strack, M.D., Ph.D., presented research spotlighting hypoglycemia-related burdens among adults with T1D using automated insulin delivery (AID) systems at the inaugural Breakthrough T1D Clinical & Research Congress (CRC 2026) in Philadelphia, PA. Cadisegliatin is a potential first-in-class,

vTv Therapeutics Announces Oral Presentation at Breakthrough T1D Clinical and Research Congress 2026

Sat, 10 Oct 2026 08:00:00 -0400

New research spotlights hypoglycemia-related burdens in adults with type 1 diabetes using automated insulin delivery systems

Form SCHEDULE 13G/A vTv Therapeutics Inc. Filed by: MILLENNIUM MANAGEMENT LLC

Thu, 08 Oct 2026 18:27:00 -0400

si-local-file:///var/storage/secattach/20261008/27167899.html

vTv Therapeutics stock jumps on FDA orphan drug status

Thu, 08 Oct 2026 09:18:18 -0400

Investing.com -- vTv Therapeutics Inc (NASDAQ:VTVT) shares rose 6.4% in premarket trading Thursday after the company announced on Wednesday evening that the FDA granted orphan drug designation to HPPD, its oral Nrf2/Bach1 modulator being investigated as a treatment for sickle cell disease.

The designation reinforces the unmet need in sickle cell disease and strengthens the company's ability to advance strategic partnering discussions for HPPD, according to Paul Sekhri, Chairman, President, and CEO of vTv Therapeutics. The company continues to prioritize cadisegliatin, its lead late-stage type 1 diabetes program.

HPPD is an investigational, oral, first-in-class Nrf2/Bach1 modulator. Preclinical studies conducted

vTv Therapeutics stock jumps on FDA orphan drug status

Thu, 08 Oct 2026 09:18:18 -0400

HPPD is an investigational, oral, first-in-class Nrf2/Bach1 modulator. Preclinical studies conducted

FDA grants orphan drug status to vTv Therapeutics' sickle cell drug

Wed, 07 Oct 2026 16:11:24 -0400

vTv Therapeutics Inc. (Nasdaq: VTVT) announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation to HPPD (HPP8668), the company's investigational oral Nrf2/Bach1 modulator being studied as a treatment for sickle cell disease.

The designation applies to an early-stage compound that vTv says it intends to advance through partnering discussions, while the company continues to focus primary resources on cadisegliatin, its late-stage type 1 diabetes program.

Preclinical studies conducted at Augusta University using the Townes sickle cell disease mouse model showed that HPPD was orally active and well tolerated, increased fetal hemoglobin, and reduced oxidative stress and red blood

FDA grants orphan drug status to vTv Therapeutics' sickle cell drug

Wed, 07 Oct 2026 16:11:24 -0400

vTv Therapeutics Announces FDA Orphan Drug Designation for HPPD in Sickle Cell Disease

Wed, 07 Oct 2026 16:01:00 -0400

Milestone supports partnering discussions for HPPD as the Company continues to prioritize its lead late-stage type 1 diabetes (T1D) program, cadisegliatin

HIGH POINT, N.C., Oct. 07, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company advancing cadisegliatin, a novel oral investigational therapy for type 1 diabetes (T1D), today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to HPPD, the Company’s oral, first-in-class Nrf2/Bach1 modulator. HPPD is being investigated as a treatment for sickle cell disease.

“The FDA’s Orphan Drug Designation reinforces both the urgency of the unmet need

vTv Therapeutics Announces FDA Orphan Drug Designation for HPPD in Sickle Cell Disease

Wed, 07 Oct 2026 16:01:00 -0400

Milestone supports partnering discussions for HPPD as the Company continues to prioritize its lead late-stage type 1 diabetes (T1D) program, cadisegliatin

“The FDA’s Orphan Drug Designation reinforces both the urgency of the unmet need

Form 8-K vTv Therapeutics Inc. For: Oct 01

Tue, 06 Oct 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20261006/27155958.html

vTv Therapeutics to host KOL event on type 1 diabetes drug program

Tue, 06 Oct 2026 08:00:39 -0400

vTv Therapeutics Inc. (Nasdaq: VTVT) announced it will host a virtual key opinion leader event on Oct. 20, 2026, at 2:30 p.m. ET, focused on hypoglycemia in type 1 diabetes and its Phase 3 cadisegliatin program.

The event will feature Schafer Boeder, MD, of Paradigm Clinical Research and the University of California San Diego, and Klara Klein, MD, PhD, of the University of North Carolina at Chapel Hill, along with company management. Cellist and type 1 diabetes advocate Alisa Weilerstein will also participate.

Topics to be discussed include the current type 1 diabetes treatment landscape, hypoglycemia risk, and an overview of the

vTv Therapeutics to Host Virtual KOL Event on Hypoglycemia in Type 1 Diabetes and the Cadisegliatin Phase 3 Program on October 20, 2026

Tue, 06 Oct 2026 08:00:00 -0400

HIGH POINT, N.C., Oct. 06, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company advancing cadisegliatin, a novel oral investigational therapy for type 1 diabetes (T1D), today announced that it will host a virtual key opinion leader (KOL) event on Tuesday, October 20, 2026, at 2:30 PM ET. To register, click here.

The event will feature leading T1D experts Schafer Boeder, MD (Paradigm Clinical Research, University of California San Diego), Klara Klein, MD, PhD (University of North Carolina at Chapel Hill School of Medicine), and acclaimed cellist

vTv Therapeutics to Host Virtual KOL Event on Hypoglycemia in Type 1 Diabetes and the Cadisegliatin Phase 3 Program on October 20, 2026

Tue, 06 Oct 2026 08:00:00 -0400

vTv Therapeutics completes enrollment in Phase 3 type 1 diabetes trial

Mon, 05 Oct 2026 08:00:29 -0400

vTv Therapeutics Inc. (Nasdaq: VTVT) announced the completion of enrollment in its Phase 3 CATT1 study evaluating cadisegliatin as an adjunctive therapy for type 1 diabetes (T1D), according to a company statement.

A total of 166 patients have been randomized in the randomized, double-blind, placebo-controlled study. Participants were assigned to receive cadisegliatin 800 mg once daily, cadisegliatin 800 mg twice daily, or placebo over six months. The study enrolls adults aged 18 and older with T1D who use multiple daily insulin injections or continuous subcutaneous insulin infusion alongside continuous glucose monitoring.

The primary efficacy endpoint measures the incidence of level 2 and

vTv Therapeutics Announces Completion of Enrollment in Phase 3 CATT1 Study of Cadisegliatin in Type 1 Diabetes (T1D)

Mon, 05 Oct 2026 08:00:00 -0400

Milestone advances Phase 3 program toward topline results expected in mid 2027

HIGH POINT, N.C., Oct. 05, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company advancing cadisegliatin, a novel oral investigational therapy for type 1 diabetes (T1D), today announced that the Company has completed enrollment of its Phase 3 Cadisegliatin as Adjunctive Therapy in Type 1 Diabetes (CATT1) study. A total of 166 patients have been randomized in the study evaluating cadisegliatin, a potential first-in-class oral, liver-selective glucokinase activator that has received Breakthrough Therapy designation from the U.S. Food and

vTv Therapeutics Announces Completion of Enrollment in Phase 3 CATT1 Study of Cadisegliatin in Type 1 Diabetes (T1D)

Mon, 05 Oct 2026 08:00:00 -0400

Milestone advances Phase 3 program toward topline results expected in mid 2027

vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Tue, 15 Sep 2026 16:05:00 -0400

HIGH POINT, N.C., Sept. 15, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes (T1D), today announced that it granted 2,500 stock options to purchase shares of common stock to a non-executive employee as a material inducement to employment in accordance with Nasdaq Listing Rule 5635(c)(4).

The stock options that were granted at an exercise price of $31.44 per share. Each option award will vest over a 4-year period, with

vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Tue, 15 Sep 2026 16:05:00 -0400

The stock options that were granted at an exercise price of $31.44 per share. Each option award will vest over a 4-year period, with

vTv Therapeutics to Participate in September Investor Conferences

Wed, 02 Sep 2026 08:00:00 -0400

HIGH POINT, N.C., Sept. 02, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company advancing cadisegliatin, a novel oral investigational therapy for type 1 diabetes (T1D), today announced that management will participate in the following investor conferences in September:

H.C. Wainwright 28th Annual Global Investment Conference
Format: Fireside Chat and one-on-one investor meetings
Date: Wednesday, September 16, 2026
Time: 10:00-10:30 AM ET
Location: New York, NY
Webcast Link

5th Annual ROTH Healthcare Opportunities Conference
Format: One-on-one investor meetings
Date: Tuesday, September 29, 2026

About vTv Therapeutics